Image Metrix chosen as CRO for Image Management in AMI Bone Imaging Trial
ACR Image Metrix chosen as CRO for Image Management in Groundbreaking AMI Bone Imaging Trial
(January 27, 2009; Philadelphia, PA)-An innovative clinical trial designed to compare two bone-imaging techniques will utilize more than 300 patients at 11 different sites in the U.S.
ACR Image Metrix has been selected by the Academy of Molecular Imaging (AMI) to be the contract research organization (CRO) providing database/data management and image handling resources for a groundbreaking trial comparing 18F-Sodium Fluoride PET/CT imaging with conventional 99mTc-MDP bone-imaging techniques to localize carcinogenic bone metastasis.
“Our unique connection with the American College of Radiology (ACR) has shown to give us tremendous creditability from the start,” said Michael J. Morales, ACR Image Metrix general manager. “It positions us as having both the scientific and operational horsepower to compete at a very high level in the CRO marketplace.”
“Recent trials at ACR Image Metrix have focused on the capacity of molecular and functional imaging to serve as biomarkers in determining the effectiveness of anticancer treatments,” Morales said. “We were a natural partner for AMI.”
AMI has secured funding from the Institute for Molecular Technologies (IMT), as well as broad academic collaboration. Among participating institutions are Duke, Stanford and Dartmouth Universities, Memorial Sloan-Kettering, MD Anderson and Cedars-Sinai Medical Center.
About ACR Image Metrix
ACR Image Metrix, located in the American College of Radiology Clinical Research Center, applies imaging techniques as a predictive and prognostic biomarker improving the efficiency for drug development programs. The world-class team of physicians and scientists at ACR Image Metrix work with pharmaceutical, biotech and medical device companies to increase the efficiency of drug and device development programs by integrating the appropriate imaging modalities. ACR Image Metrix has years of experience and proven expertise in employing state-of-the-art technologies provide a complete line of imaging services.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
